| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/03/2009 | EP0833649B2 Methods of preventing or treating allergies |
| 06/03/2009 | EP0772677B1 T cell activation |
| 06/03/2009 | CN101448519A Use of thymosin alpha 1 for the treatment of immunological diseases |
| 06/03/2009 | CN101448518A Pharmaceutical composition containing the nmb0606 protein |
| 06/03/2009 | CN101448517A Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease |
| 06/03/2009 | CN101448516A Cyclised alpha-conotoxin peptides |
| 06/03/2009 | CN101448515A Pharmaceutical compositions |
| 06/03/2009 | CN101448514A Treatment of melanoma |
| 06/03/2009 | CN101448513A Methods and compositions related to improving properties of pharmacological agents targeting nervous system |
| 06/03/2009 | CN101448512A Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| 06/03/2009 | CN101445802A Novel porcine circovirus virus, vaccines and diagnosis agent |
| 06/03/2009 | CN101445463A Beta2-adrenergic receptor agonists |
| 06/03/2009 | CN101444624A Medicine for cancer therapy |
| 06/03/2009 | CN101444621A Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (FGE) |
| 06/03/2009 | CN101444620A Cream for resisting oxidation and eliminating insomnia and preparation method thereof |
| 06/03/2009 | CN101444619A Formula for lyophilized preparation of human serum albumin-free cytokine |
| 06/03/2009 | CN101444618A Pharmaceutical preparation containing exenatide |
| 06/03/2009 | CN100495028C A process for the isolation of a major harmful oxidant from cigarette smoke |
| 06/03/2009 | CN100494363C Glycooxidase and its application in baking process |
| 06/03/2009 | CN100494213C Process for preparing synergistic factor in artificial blood, nucleotide sequence used thereby |
| 06/03/2009 | CN100493647C Sustained release of an active agent using an implantable system |
| 06/03/2009 | CN100493606C Use of human lysozyme in preparing medicines for cutaneous pruritus |
| 06/03/2009 | CN100493605C Use of human lysozyme in preparing anti-virus medicines for influenza |
| 06/03/2009 | CN100493604C Application of hepatocyte growth promoting factors in medicine for treating diffusive interstitial pneumonia |
| 06/03/2009 | CN100493603C Gonadoliberin double-way genital regulating medicine and reproduction of fish |
| 06/03/2009 | CN100493602C Gonadoliberin double-way genital regulating medicine and reproduction of fowl |
| 06/03/2009 | CN100493601C Method of protein purification and recovery |
| 06/03/2009 | CN100493600C Pharmaceutical composition for preventing and curing endometritis and retained afterbirth disease of milk cow |
| 06/02/2009 | US7541449 DNA segment encoding the enzyme inhibitor for therapy of thrombosis, blood disorders; biodrugs; genetic vaccines; monoclonal antibodies; host cells |
| 06/02/2009 | US7541439 Thrombopoietin proteins with improved properties |
| 06/02/2009 | US7541437 Breast cancer resistance protein (BCRP) and the DNA which encode it |
| 06/02/2009 | US7541436 covalently attached to a nonpeptide polyoxyethylene glycol moiety; nucleic acids encoding the polypeptides; reducing the number of copies of a virus in infected cells; drugs/polymer conjugates/ as viricides treating Hepatitis-C virus |
| 06/02/2009 | US7541435 Antagonists of cxcr3-binding cxc chemokines |
| 06/02/2009 | US7541430 Cyclic and linear peptides useful in the treatment of obesity which are specific to one or more melanocortin receptor and which exert a prolonged activity; use of the peptides in therapy and in the manufacture of medicaments |
| 06/02/2009 | US7541428 Tumor antigen protein SART-3 and tumor antigen peptides thereof |
| 06/02/2009 | US7541343 Antiproliferative agents; administering protein; restenosis, atherosclerosis; cancer |
| 06/02/2009 | US7541340 In a cell by contacting cell with an aromatic-cationic peptide having at least one net positive charge, a minimum of four amino acids, a maximum of about twenty amino acids; for example, where aromatic-cationic peptide comprises Phe-D-Arg-Phe-Lys-NH2; reduced Oxidized Low-Density Lipoprotein |
| 06/02/2009 | US7541339 Par-2-activating peptide derivative and pharmaceutical composition using the same |
| 06/02/2009 | US7541338 Glial mitogenic factors, their preparation and use |
| 06/02/2009 | US7541337 Methods and compositions for the treatment of peripheral artery disease |
| 06/02/2009 | US7541336 Prepared by culturing a microorganism belonging to fungi and having ability to produce FKI-1033 substance in a medium; use in agrochemicals, veterinary medicines and pharmaceuticals having an activity of ryanodine binding inhibition, an insecticidal and anthelmintic activity |
| 06/02/2009 | US7541335 Nogo-receptors and methods of use |
| 06/02/2009 | US7541334 Hybrid peptides modulate the immune response |
| 06/02/2009 | US7541333 Angiogenically effective unit dose of FGF-2 and method of use |
| 06/02/2009 | US7541332 reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity |
| 06/02/2009 | US7541331 Surfactant treatment regimen |
| 06/02/2009 | US7541330 Conjugates with reduced adverse systemic effects |
| 06/02/2009 | US7541329 Oil body associated protein compositions and methods of use thereof for reducing the risk of cardiovascular disease |
| 06/02/2009 | US7541328 Coupling proteins to a modified polysaccharide |
| 06/02/2009 | US7541183 Growth and differentiation of adult muscle stem cells with activators or inhibitors of Wnt signaling |
| 06/02/2009 | US7541181 Vector carrying a polynucleotide which encodes a GSD polypeptide from Mycobacterium paratuberculosis |
| 06/02/2009 | US7541180 comprising administering to a cells or tissues in vitro; hepatitis C virus (HCV) antigens; dna immunization |
| 06/02/2009 | US7541164 Mammalian cell culture processes for protein production |
| 06/02/2009 | US7541163 Expression vector comprising nucleotide sequences coding multifunctional protein with viricidal activity |
| 06/02/2009 | US7541157 Drug screening; amplification free; antihypertensive agent; tissue distribution of radioactivity of the molecules administered is analysed in vivo using suitable imaging devices so no killing of animal is necessary |
| 06/02/2009 | US7541154 GASP1: a follistatin domain containing protein |
| 06/02/2009 | US7541140 Assessment of serum and/or urine calcium levels by determining the concentration of parathyroid hormone (PTH) agonist and that of PTH antagonist in a sample; comparingand averaging ratios; amino acid sequences of both; diagnosis/medical/; prognosis; metabolism/absorption of calcium calculi |
| 06/02/2009 | US7541139 Tryptophan as a functional replacement for ADP-ribose-arginine in recombinant proteins |
| 06/02/2009 | US7541044 stimulating antitumor immune responses; tissue-targeted therapy; first tumour antigen is used to treat secondary tumor; biodrug for cancer immunotherapy with cyclophosphamide |
| 06/02/2009 | US7541039 Vaccine delivery; attaching immunogenic determinant of heterologous polypeptide biodrug to the peptidoglycan microparticle on cell wall of a Gram-positive bacterium; improve the binding by treating the cell wall with acid solution to remove protein, lipotechoic, carbohydrates |
| 06/02/2009 | US7541036 Human immunodeficiency virus type 1 (HIV-1) matrix (MA or p17) polypeptide capable of inducing anti-p17 antibodies that neutralize the proinflammatory activities of the MA protein |
| 06/02/2009 | US7541034 Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
| 06/02/2009 | US7541032 Antigen uptake receptor for Candida albicans on dendritic cells |
| 06/02/2009 | US7541031 Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα |
| 06/02/2009 | US7541028 shell portion of biodegradable positively charged chitosan, a core of negatively charged substrate of polyglutamic acid; administer monoclonal antibodies orally in nanoparticles that provide enhanced paracellular permeability, bioavailability, and sustained release |
| 06/02/2009 | US7541027 polyclonal antibodies, monoclonal antibodies, F(ab')2, Fab and single chain Fv; tyrosine at position 1214 in the amino acid sequence of the vascular endothelial growth factor receptor |
| 06/02/2009 | US7541026 Alpha-amylase variants with altered properties |
| 06/02/2009 | US7541018 Treatment process using somatostatin analogues |
| 06/02/2009 | US7540382 Stabilized liquid protein formulations in pharmaceutical containers |
| 06/02/2009 | CA2349633C A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state |
| 06/02/2009 | CA2340416C Co-lyophilized complex of a nucleic acid vector and a formulating agent |
| 06/02/2009 | CA2335937C Azaftig, a proteoglycan for monitoring cachexia and for control of obesity |
| 06/02/2009 | CA2321664C Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 06/02/2009 | CA2274495C Uspa1 and uspa2 antigens of moraxella catarrhalis |
| 06/02/2009 | CA2249351C Novel method of diagnosing and treating gliomas |
| 06/02/2009 | CA2247388C Pharmaceutical composition comprising serum amyloid p component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components |
| 06/02/2009 | CA2226548C Lyophilized hepatocyte growth factor preparations |
| 06/02/2009 | CA2190867C Methods for reduced renal uptake of antibody fragments |
| 06/02/2009 | CA2189947C Use of von willebrand factor and pharmaceutical formulation |
| 06/02/2009 | CA2178208C Purification of vitamin-k dependent proteins by membrane chromatography |
| 06/02/2009 | CA2158475C Composition and method for reducing toxicity of biologically-active factors |
| 05/28/2009 | WO2009067639A2 Variants of c-type natriuretic peptide |
| 05/28/2009 | WO2009067584A1 Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution |
| 05/28/2009 | WO2009067407A2 Compositions of matrix metalloproteinase activating endopeptidases for reducing intraocular pressure, and methods of use thereof |
| 05/28/2009 | WO2009067268A1 Methods of enhancing diabetes resolution |
| 05/28/2009 | WO2009067191A2 Methods and compositions for the treatment of hepatitis c virus (hcv) infection |
| 05/28/2009 | WO2009066763A1 Preparation for application to body surface and preparation holding sheet for application to body surface |
| 05/28/2009 | WO2009066468A1 Particulate medical material and use thereof |
| 05/28/2009 | WO2009066462A1 Method for induction of cytotoxic t-cell, cytotoxic t-cell inducer, and pharmaceutical composition and vaccine each comprising the inducer |
| 05/28/2009 | WO2009066299A2 Use of haptoglobin genotyping in diagnosis and treatment of cardiovascular disease |
| 05/28/2009 | WO2009066174A1 Improved cytokine design |
| 05/28/2009 | WO2009066010A1 Method for detecting nt-probnp or the nt-probnp/probnp ratio |
| 05/28/2009 | WO2009065994A1 Use of inductor agents gse24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence |
| 05/28/2009 | WO2009065918A1 Stabilisation of liquid-formulated factor vii(a) polypeptides by aldehyde-containing compounds |
| 05/28/2009 | WO2009065897A2 Inhibitors of malt1 proteolytic activity and uses thereof |
| 05/28/2009 | WO2009065857A2 Compositions for reducing oxidative stress and uses thereof |
| 05/28/2009 | WO2009065561A2 System for delivery into a xcr1 positive cell and uses thereof |
| 05/28/2009 | WO2009065296A1 Gene engineering immunorepressive polypeptides and their preparing methods and uses |
| 05/28/2009 | WO2009065292A1 Fusion protein comprising tumor necrosis factor related apoptosis inducing ligand and integrin ligand and use thereof |
| 05/28/2009 | WO2009065217A1 Novel immunoregulatory peptides, compositions and uses thereof |